Jennifer Kayden Lee
CIK: 0001801372
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
RHYTHM PHARMACEUTICALS, INC.
Discretionary Trading P&L
Holdings
Transaction History (34 total)
- Aug 13, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct35K shares at avg. $24.29$850K - Aug 13, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct21.6K shares at avg. $6.80$147K - Aug 13, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct75.8K shares at avg. $117.38$8.9M - Feb 11, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectStock Options (Right to Buy)
32.5K shares- - Feb 11, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Units
21.7K shares- - Feb 1, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Tax Payment(F)Direct9.2K shares at avg. $108.99$1.0M - Feb 1, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct22.6K shares- - Feb 19, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct2K shares at avg. $57.22$116K - Feb 16, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct5.5K shares- - Feb 14, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Units
36.7K shares- - Feb 14, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectStock Options (Right to Buy)
55K shares- - Feb 13, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct1.2K shares at avg. $58.00$70K - Feb 12, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct600 shares at avg. $56.39$34K - Feb 12, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct1.2K shares at avg. $56.39$68K - Feb 12, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct10 shares at avg. $56.41$564.1 - Feb 11, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct4 shares at avg. $57.50$230 - Feb 11, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct2K shares- - Feb 11, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct1K shares at avg. $57.51$59K - Feb 10, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct2.3K shares at avg. $59.34$136K - Feb 10, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct1.9K shares at avg. $58.39$111K - Feb 9, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct3.4K shares- - Feb 9, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct4.2K shares at avg. $6.80$28K - Feb 5, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct200 shares at avg. $61.95$12K - Feb 5, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct1.7K shares at avg. $60.08$104K - Feb 5, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct1.1K shares at avg. $61.01$69K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 13, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 35,000 | $24.29 | $850,150 | Direct |
| Aug 13, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 21,601 | $6.80 | $146,887 | Direct |
| Aug 13, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 75,834 | $117.38 | $8,901,531 | Direct |
| Feb 11, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Stock Options (Right to Buy) | 32,500 | - | - | Direct |
| Feb 11, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Restricted Stock Units | 21,650 | - | - | Direct |
| Feb 1, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Tax Payment(F) | 9,237 | $108.99 | $1,006,741 | Direct |
| Feb 1, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 22,612 | - | $0 | Direct |
| Feb 19, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 2,035 | $57.22 | $116,443 | Direct |
| Feb 16, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 5,500 | - | - | Direct |
| Feb 14, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Restricted Stock Units | 36,650 | - | - | Direct |
| Feb 14, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Stock Options (Right to Buy) | 55,000 | - | - | Direct |
| Feb 13, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 1,205 | $58.00 | $69,890 | Direct |
| Feb 12, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 600 | $56.39 | $33,834 | Direct |
| Feb 12, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 1,205 | $56.39 | $67,950 | Direct |
| Feb 12, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 10 | $56.41 | $564 | Direct |
| Feb 11, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 4 | $57.50 | $230 | Direct |
| Feb 11, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 2,031 | - | - | Direct |
| Feb 11, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 1,023 | $57.51 | $58,833 | Direct |
| Feb 10, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 2,295 | $59.34 | $136,187 | Direct |
| Feb 10, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 1,894 | $58.39 | $110,596 | Direct |
| Feb 9, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 3,437 | - | - | Direct |
| Feb 9, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 4,189 | $6.80 | $28,485 | Direct |
| Feb 5, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 200 | $61.95 | $12,390 | Direct |
| Feb 5, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 1,733 | $60.08 | $104,121 | Direct |
| Feb 5, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 1,133 | $61.01 | $69,130 | Direct |
1-25 of 34 transactions
About Lee Jennifer Kayden
Lee Jennifer Kayden (SEC CIK 0001801372) files insider reports with the SEC as EVP, Head of North America of RHYTHM PHARMACEUTICALS, INC. (RYTM).
Signal8 holds 9 ownership filings by Lee Jennifer Kayden, all Form 4s, filed between Nov 13, 2024 and Aug 14, 2026. Those filings report 34 transactions, from Nov 11, 2024 to Aug 13, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Lee Jennifer Kayden's filings is in BOSTON, MA.
Recent filings by Lee Jennifer Kayden
- Aug 13, 2026: Option exercises of RYTM shares (2 lines, Form 4, code M).
- Aug 13, 2026: Open-market sale of RYTM shares (Form 4, code S).
- Feb 11, 2026: Grants or awards of RYTM derivative securities (2 lines, Form 4, code A).
- Feb 1, 2026: Tax withholding of RYTM shares (Form 4, code F).
- Feb 1, 2026: Option exercise of RYTM shares (Form 4, code M).
Other insiders filing for RHYTHM PHARMACEUTICALS, INC. (RYTM)
- Meeker David P, President and CEO
- Smith Hunter C, Chief Financial Officer
- Joshi Manher, Chief Medical Officer
- Shulman Joseph, Chief Technical Officer
- Garfield Alastair, Chief Scientific Officer
- Mazabraud Yann, EVP, Head of International